PubRank

E Petru

Author PubWeight™ 31.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999 1.34
2 Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 2001 1.33
3 Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 1999 1.24
4 Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995 1.17
5 Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999 1.01
6 Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 2011 1.00
7 Spontaneous vaginal delivery in the birth-chair versus in the conventional dorsal position: a matched controlled comparison. Wien Klin Wochenschr 2001 0.98
8 Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998 0.94
9 Vesicocutaneous fistula mimicking an abdominal wall abscess 2 years after radical abdominal hysterectomy. Gynecol Oncol 2003 0.91
10 Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 2006 0.91
11 [Wound rupture after Misgav-Ladach cesarean section: a case report]. Gynakol Geburtshilfliche Rundsch 2004 0.90
12 Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 2011 0.90
13 Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 2001 0.89
14 Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma. Int J Gynecol Cancer 2001 0.87
15 Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000 0.86
16 Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: A case report. Gynecol Oncol 1999 0.86
17 Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report. Anticancer Res 2006 0.85
18 Primary serous papillary carcinoma of the peritoneum: a report of 18 patients. Eur J Gynaecol Oncol 1997 0.83
19 Cord blood oxygen saturation in vigorous infants at birth: what is normal? BJOG 2000 0.82
20 The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999 0.82
21 Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol 1993 0.81
22 In vitro chemosensitivity testing in the treatment of ovarian carcinoma. Arch Gynecol Obstet 1989 0.81
23 Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass. Anticancer Res 2001 0.79
24 Do primiparas aged 40 years or older carry an increased obstetric risk? Prev Med 1999 0.79
25 [Importance of the composition of various combination regimens in the chemotherapy of metastatic breast cancer]. Dtsch Med Wochenschr 1987 0.79
26 On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschr 1986 0.79
27 Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. Am J Obstet Gynecol 1991 0.79
28 Feasible model for locoregional and systemic longterm administration of drugs and concomitant blood sampling in Sprague-Dawley rats. J Cancer Res Clin Oncol 1987 0.78
29 Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol 1990 0.77
30 Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. J Cancer Res Clin Oncol 2008 0.77
31 Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing. Int J Clin Pharmacol Ther 1999 0.77
32 Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotropin secretion during chemotherapy for choriocarcinoma. Gynecol Oncol 2001 0.76
33 Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study. Am J Clin Oncol 1991 0.76
34 Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma. J Cancer Res Clin Oncol 1987 0.76
35 Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res 2001 0.75
36 Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res 2002 0.75
37 Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006 0.75
38 Influence of perinatal nicotine administration on transplacental carcinogenesis in Sprague Dawley rats by N-methylnitrosourea. Br J Cancer 1987 0.75
39 Re: "Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy". Gynecol Oncol 2005 0.75
40 Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Res Treat 1991 0.75
41 Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol 1997 0.75
42 [Chemotherapeutic characterization of new nitrosourea compounds]. Arch Geschwulstforsch 1988 0.75
43 [Hydatidiform mole, trophoblastic tumor/choriocarcinoma]. Gynakol Geburtshilfliche Rundsch 1992 0.75
44 [Scalenus biopsy in diagnosis of ovarian and uterine cancers]. HNO 1990 0.75
45 [Therapeutic effectiveness of various combination chemotherapy protocols in advanced epithelial ovarian cancer]. Geburtshilfe Frauenheilkd 1986 0.75
46 Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study. Anticancer Res 2002 0.75
47 Long-term disease-free survival after breast cancer metastatic to the ovary. Int J Gynecol Cancer 2002 0.75
48 Influence of the application mode of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide on the localization of its carcinogenic expression in female NMRI-mice. Cancer Lett 1986 0.75
49 Perioperative antibiotic prophylaxis in patients undergoing radical surgery for gynecologic cancer: single dose versus multiple dose administration. Eur J Gynaecol Oncol 1993 0.75
50 [Therapy of uterine cancer: a review]. Gynakol Rundsch 1988 0.75
51 [Change in obstetrical risk in adolescent primiparous patients--a comparative study]. Gynakol Rundsch 1989 0.75
52 [Risk of cancer in cyclophosphamide therapy of multiple sclerosis]. Dtsch Med Wochenschr 1987 0.75
53 Prognostic implications of residual tumour volume in stage III ovarian cancer patients undergoing adjuvant cytotoxic chemotherapy. Baillieres Clin Obstet Gynaecol 1989 0.75
54 [Immunity of habitual abortion. Principles and current status of research]. Gynakol Rundsch 1988 0.75
55 [Primary malignant non-Hodgkin's lymphoma of the breast: breast preserving therapy in 3 patients]. Gynakol Geburtshilfliche Rundsch 1997 0.75
56 Pelvic and para-aortic lymphadenectomy in cervical cancer. Baillieres Clin Obstet Gynaecol 1988 0.75
57 Carcinogenicity of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3- nitrosoureahydrochloride and three related N-nitroso derivatives following repeated intravenous administration to male Wistar rats. Oncology 1988 0.75
58 [Diagnostic value of combined vaginal ultrasound and hysteroscopy in peri- and postmenopausal bleeding]. Gynakol Geburtshilfliche Rundsch 1996 0.75
59 [Peripartum aortic dissection]. Anaesthesist 2013 0.75
60 [Lymph node status in corpus and cervix cancer]. Gynakol Rundsch 1991 0.75
61 Combination treatment based on metabolic effects of dinaline. J Cancer Res Clin Oncol 1995 0.75
62 [Aggressive follow-up of a young patient with small cell cervix cancer]. Gynakol Geburtshilfliche Rundsch 1993 0.75
63 [Perinatal stress factors and sudden infant death (SIDS)]. Gynakol Rundsch 1988 0.75
64 Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2. Cancer Immunol Immunother 1991 0.75
65 [Lymph cysts following radical operations of cervix and ovarian cancer]. Gynakol Rundsch 1990 0.75
66 Can routine gynecologic examination contribute to the diagnosis of cervical involvement by primary endometrial cancer? Eur J Gynaecol Oncol 2009 0.75
67 Cytostatic activity of an estradiol-linked nitrosourea in MXT mammary carcinoma and L 5222 leukemia. Arzneimittelforschung 1989 0.75
68 [The obstetric risk in adolescent primiparous females]. Geburtshilfe Frauenheilkd 1989 0.75
69 [Pretherapeutic scalenus biopsy in ovarian cancer]. Gynakol Rundsch 1991 0.75
70 [Current status of diagnosis and therapy of trophoblast tumors]. Gynakol Rundsch 1990 0.75
71 [Secondary tumors following cytostatic chemotherapy with alkylating agents in man; the toxicological viewpoints]. Dtsch Med Wochenschr 1986 0.75
72 Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery. Oncology 1989 0.75
73 Concomitant endometrial hyperplasia in patients with endometrial carcinoma. Gynecol Oncol 1998 0.75
74 [The value of preventive ovariectomy at the time of hysterectomy for prevention of ovarian cancer]. Gynakol Rundsch 1991 0.75
75 [Chemotherapy and prognostic significance of the size of the remaining tumor in ovarian cancer]. Gynakol Rundsch 1989 0.75